echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > JECCR Zhengzhou University Professor Wei Cao’s team reveals a new mechanism for the occurrence of esophageal squamous cell carcinoma

    JECCR Zhengzhou University Professor Wei Cao’s team reveals a new mechanism for the occurrence of esophageal squamous cell carcinoma

    • Last Update: 2021-09-30
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Editor’s note iNature is China’s largest academic official account.
    It is jointly created by the doctoral team of Tsinghua University, Harvard University, Chinese Academy of Sciences and other units.
    The iNature Talent Official Account is now launched, focusing on talent recruitment, academic progress, scientific research information, interested parties can Long press or scan the QR code below to follow us
    .

    iNature esophageal cancer is one of the most deadly malignant tumors in the world, and poses a serious challenge to global human health1
    .

    Due to the uncontrolled growth and recurrence of tumors, the five-year survival rate of patients with advanced esophageal cancer is still low
    .

    Therefore, in-depth exploration of the mechanism of esophageal cancer will help promote the development of new clinical targeted therapeutic drugs
    .

    On September 21, 2021, Professor Cao Wei’s team from Zhengzhou Central Hospital Affiliated to Zhengzhou University and Professor Guan Fangxia’s research group from the School of Life Sciences of Zhengzhou University jointly published the title "RNA m6A demethylase FTO-mediated epigenetic up-regulation" in the Journal of Experimental&Clinical Cancer Research.
    of LINC00022 promotes tumorigenesis in esophageal squamous cell carcinoma" research paper, this study reveals for the first time that N6-methyladenosine (m6A) demethylase FTO and its mediated long-chain non-coding RNA (LncRNA) LINC00022 in esophageal squamous cell carcinoma It plays an important role in carcinogenesis and provides candidate molecular targets for targeted therapy of esophageal squamous cell carcinoma
    .

    RNA m6A modification is currently considered to be one of the key factors to maintain the biological characteristics of tumor cells
    .

    Studies have shown that dysregulated m6A regulatory factors affect the stability and translation efficiency of mRNA by changing the level of m6A modification of mRNA molecules, thereby regulating biological processes such as tumor proliferation and metastasis 2-3
    .

    LncRNA plays an important role in the progression of esophageal squamous cell carcinoma and other malignant tumors.
    The condition-specific and tissue-specific expression pattern of LncRNA shows its great potential as a tumor clinical target and biomarker 4
    .

    However, how m6A modification regulates the function of LncRNA and its role in the development of esophageal squamous cell carcinoma is still unclear
    .

    This study identified a new esophageal squamous cell carcinoma-related LncRNA LINC00022 (Figure 1) through bioinformatics methods and deeply explored the role and mechanism of LINC00022 in the occurrence of esophageal squamous cell carcinoma.
    The high expression state in esophageal squamous cell carcinoma, LINC00022 affects the cell cycle progression by regulating the instability of the tumor suppressor protein p21 and drives the occurrence of esophageal squamous cell carcinoma
    .

    This study provides new insights into the role of m6A modification and regulation of LncRNA in the occurrence of esophageal squamous cell carcinoma, and provides a new reference for the prevention and treatment of esophageal squamous cell carcinoma
    .

    Figure 1-LINC00022 is highly expressed in esophageal squamous cell carcinoma and is a potential biomarker.
    This study was completed by Professor Cao Wei from Zhengzhou Central Hospital affiliated to Zhengzhou University and Professor Guan Fangxia's research group from the School of Life Sciences, Zhengzhou University.
    Professor Cao Wei and Professor Guan Fangxia The corresponding author of the paper, Central Hospital Cui Yuanbo is the first author and co-corresponding author of the paper
    .

    This research work was supported by the National Natural Science Foundation of China (U2004201), Henan Medical Science Research Fund (SB201903032, SBGJ202003053) and other funds
    .

    Reference: Sung H, et al.
    Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
    CA Cancer J Clin.
    2021, 71(3):209-249.
    Huang H, et al.
    Recognition of RNA N6-methyladenosine by IGF2BP proteins enhances mRNA stability and translation.
    Nat Cell Biol.
    2018, 20(3):285-295.
    Wang Q, et al.
    METTL3-mediated m6A modification of HDGF mRNA promotes gastric cancer progression and has prognostic significance.
    Gut.
    2020, 69(7):1193-1205.
    Liu SJ, et al.
    Long noncoding RNAs in cancer metastasis.
    Nat Rev Cancer.
    2021, 21(7):446-460Statello L, et al.
    Gene regulation by long non-coding RNAs and its biological functions.
    Nat Rev Mol Cell Biol.
    2021, 22(2):96-118.
    Article link: https://jeccr.
    biomedcentral.
    com/articles/10.
    1186/s13046-021-02096 -1
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.